How volatile is Amgen Inc.?

Over the past year, Amgen Inc. had an annualised volatility of 29.70%, based on daily closes. Its deepest fall from a high in that time was 16.57%, from February 27, 2026 to May 4, 2026. Its beta against the S&P 500 was 0.44.

What was the biggest price drop for Amgen Inc.?

The deepest fall in our weekly price history since November 2006 was 45.98%, from a high in the week of January 15, 2007 to a low in the week of March 17, 2008. The price regained that high in the week of July 9, 2012.

Which month has historically been best for Amgen Inc.?

Since 2015, July has had the highest average return for Amgen Inc. (+4.71%, up in 10 of 12 years) and September the lowest (-2.69%, up in 3 of 12 years). Past seasonal patterns do not predict future returns.

stock · yahoo

Amgen Inc.

AMGN

$466.01

▲ 5.28 (1.15%)

polled

Below: live stock price for Amgen Inc. (AMGN), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

Amgen Inc. (AMGN) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 31,500 people. Over the past year AMGN traded between 292.12 and 475.65 USD. Trailing P/E sits near 28.94 on a market cap of about 251.94B USD. It currently yields 2.16% in dividends.

Day

+1.15%

+5.28

Week

+6.09%

+26.75

Month

+14.42%

+58.74

Year

+56.15%

+167.58

Prev close: $460.73
Volume (24h): $1.53B
Market cap: $251.94B
Currency: USD

Score

52/ 100 · Mixed

Coverage: 7/7

Value14
Quality84
Momentum72
Growth69
Risk50
Dividend43
Liquidity31

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 4%Pace +0.06% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 467.0675
+20 bars: 468.5307
+60 bars: 469.0979
+120 bars: 469.1187

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±2.14% per bar.

Interpretation

Composite signals look mixed. Strength: quality with weakness: valuation. Price sits near the upper third of the recent range, trend is roughly flat.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
14/100
Value looks fragile — driven by P/E (28.94).
P/E:28.94P/B:21.55PEG:2.75
Quality
84/100
Quality looks strong — driven by ROE (91.47%).
ROE:91.47%ROA:8.67%Profit margin:22.95%Gross margin:71.89%
Momentum
72/100
Momentum looks solid — driven by 52w change (57.28%).
52w change:57.28%
Growth
69/100
Growth looks solid — driven by Earnings growth (64.90%).
Revenue growth:9.50%Earnings growth:64.90%
Risk
50/100
Risk looks mixed — driven by Debt / equity (490.28).
Beta:0.41Debt / equity:490.28Short interest:2.48%
Dividend
43/100
Dividend looks weak — driven by Payout ratio (60.87%).
Dividend yield:2.16%Payout ratio:60.87%
Liquidity
31/100
Liquidity looks weak — driven by Current ratio (1.37).
Current ratio:1.37Quick ratio:0.95

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 252 days.

Position in range95%

288 low475.645 high

Where the price sits between the window low and high.

Volatility (annualised): 29.7%
Max drawdown: -16.6%
Below period high: -2.0%
Best day: +8.15%
Worst day: -10.08%
Up days: 53%
Current streak: 5 up
Typical day swing: 2.3%
Volume vs average: +4%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

503.1673 USD+7.97%

Fib +27.2% extension

Next level below

451.7653 USD-3.06%

Fib 23.6% retracement

Levels derived from: 475.645 high → 374.46 low · 60 bars

Resistance
Fib +161.8% extension
not reached
639.3623 USD
+37.20% from current
Resistance
Fib +100% extension
not reached
576.83 USD
+23.78% from current
Resistance
Fib +61.8% extension
not reached
538.1773 USD
+15.49% from current
Resistance
Fib +27.2% extension
not reached
503.1673 USD
+7.97% from current
Current
466.01 USD
Support
Fib 23.6% retracementNearest
tested 1×
451.7653 USD
-3.06% from current
Support
Fib 38.2% retracement
tested 13×
436.9923 USD
-6.23% from current
Support
Fib 50% midpoint
tested 4×
425.0525 USD
-8.79% from current
Support
Fib 61.8% retracement
tested 12×
413.1127 USD
-11.35% from current
Support
Fib 78.6% retracement
tested 2×
396.1136 USD
-15.00% from current
Support
Fib −27.2% extension
not reached
346.9377 USD
-25.55% from current
Support
Fib −61.8% extension
not reached
311.9277 USD
-33.06% from current
Support
Fib −100% extension
not reached
273.275 USD
-41.36% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $475.65
52w low: $292.12
52w change: 57.28%
Day high: $475.65
Day low: $465.33
P/E (TTM): 28.94
Forward P/E: 19.03
PEG: 2.75
Price / Book: 21.55
Beta (5Y): 0.41
Enterprise value: 295.25B
EV / Revenue: 7.75
EV / EBITDA: 17.1
EPS (TTM): $16.10
Forward EPS: $24.49
Dividend yield: 2.16%
Dividend rate: $10.08
Payout ratio: 60.87%
Revenue (TTM): 38.09B
EBITDA: 17.27B
Free cash flow: 8.65B
Total cash: 13.99B
Total debt: 57.3B
Debt / Equity: 490.28
Current ratio: 1.37
Quick ratio: 0.95
Profit margin: 22.95%
Gross margin: 71.89%
Return on assets: 8.67%
Return on equity: 91.47%
Shares outstanding: 540.63M
Float: 539.16M

Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 31.5Kwww.amgen.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Analyst & Risk

Consensus

Analysts' consensus via Yahoo Finance — not investment advice.

Analysts: neutral

Mean rating2.65 / 5

Analysts29

Next earnings2026-11-03

Very positive: 4Positive: 8Neutral: 17Negative: 3Very negative: 2

Analyst price target

$397.32

Mean target · 29 analysts

-14.7%

mean target vs. price

Low $225.00Now $466.01High $500.00

Beta (vs S&P 500): 0.41; very stable
52-week change: 57.28%
Short % of float: 2.48%
Short ratio (days): 4.35
Debt / Equity: 490.28; very high leverage
Current ratio: 1.37
Quick ratio: 0.95
ROE: 91.47%
ROA: 8.67%
PEG ratio: 2.75
EV / Revenue: 7.75
EV / EBITDA: 17.1
Revenue growth: 9.50%
Earnings growth: 64.90%
EBITDA: 17.27B
Free cash flow: 8.65B
Total cash: 13.99B
Total debt: 57.3B
Insider holdings: 0.23%
Institutional: 85.13%

Recent rating changes

2026-10-23OppenheimerOutperform → Outperformmain
2026-10-21BarclaysEqual-Weight → Equal-Weightmain
2026-10-13GuggenheimNeutral → Neutralmain
2026-10-12BMO CapitalMarket Perform → Market Performmain
2026-10-12Wells FargoEqual-Weight → Equal-Weightmain
2026-10-09UBSBuy → Buymain
2026-10-08RBC CapitalOutperform → Outperformmain
2026-10-08Cantor FitzgeraldNeutral → Neutralmain

Financial documents

Amgen Inc. performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$439.26	$439.26	+6.09%
1 month$421.51	$421.51	+10.56%
3 months$387.64	$387.64	+20.22%
6 months$346.25	$346.25	+34.59%
Year to date$327.31	$327.31	+42.38%
1 year$292.00	$292.00	+59.59%
3 years$261.57	$261.57	+78.16%	+21.15%
5 years$206.97	$206.97	+125.2%	+17.61%
10 years$145.18	$145.18	+221.0%	+12.36%
Since Nov 2006$73.46	$73.46	+534.4%	+9.69%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

Amgen Inc. all-time high and low

Highest since Nov 2006

$475.64

Oct 30, 2026

2.03% below the high

Lowest since Nov 2006

$39.16

week of Mar 17, 2008

1,090% above the low

52-week range

95%

Low

$288.00

Oct 31, 2025

High

$475.64

Oct 30, 2026

The latest price sits at 95% of this range.

Highs and lows include intraday prices.

Amgen Inc. risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 29.70%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -16.57%; Feb 27, 2026 → May 4, 2026 · Recovered on Jul 28, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Nov 2006): -45.98%; Jan 2007 → Mar 2008 · Recovered in the week of Jul 9, 2012.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.76; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): 0.44; On average, Amgen Inc. moved 0.44% for each 1% move in the S&P 500 on the same day.

Amgen Inc. drawdown from peak

How far the price stood below its previous high, based on weekly closes since Nov 2006.

Amgen Inc. seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

Amgen Inc. seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	+4.5%	+14%	-9.4%	-1.6%	-2.7%	+7.5%	+6.4%	+12%	-1.9%	+11%*			+42%*
2025	+8.7%	+7.9%	-0.4%

Amgen Inc. price history

Yearly open, high, low and close, newest first.

Amgen Inc. price history
Year	Open	High	Low	Close	Change
2026YTD	$328.77	$475.64	$318.21	$466.01	+42.38%
2025	$260.83	$346.38	$257.05	$327.31	+24.62%
2024	$287.28	$346.85	$253.30	$262.65	-8.81%
2023	$260.87	$289.04	$211.71	$288.02	+9.66%
2022	$223.63	$296.67	$214.39	$262.64	+16.74%

Frequently asked questions about Amgen Inc.

What is the price of Amgen Inc. today?

As of October 30, 2026, the price of Amgen Inc. is $466.01, up 1.15% from the previous close.

What is the all-time high of Amgen Inc.?

The highest price for Amgen Inc. in our data, which starts in November 2006, is $475.64, reached on October 30, 2026. At $466.01, the latest price is 2.03% below it.

How much has Amgen Inc. gained this year?

Amgen Inc. is up 42.38% so far in 2026: it closed 2025 at $327.31 and is at $466.01 now.

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	+1.6%	-0.3%	+0.5%	-0.7%	-0.1%	+2.5%	+4.7%	+1.9%	-2.7%	+0.9%	+3.4%	-0.7%	+7.3%
Years up	58%	42%	50%	25%	33%	75%	83%	50%	25%	36%	82%	45%	55%

Year	Open	High	Low	Close	Change
2021	$231.25	$276.69	$198.64	$224.97	-2.15%
2020	$241.40	$264.97	$177.05	$229.92	-4.81%
2019	$191.93	$244.99	$166.30	$241.53	+26.63%
2018	$175.35	$210.19	$163.31	$190.73	+9.68%
2017	$147.86	$191.10	$147.12	$173.90	+18.94%
2016	$159.00	$176.85	$133.64	$146.21	-9.93%
2015	$163.83	$181.81	$130.09	$162.33	-0.69%
2014	$115.36	$173.14	$108.20	$163.46	+41.99%
2013	$85.00	$119.70	$81.56	$115.12	+35.05%
2012	$64.95	$90.81	$63.30	$85.24	+32.75%
2011	$55.20	$65.00	$47.66	$64.21	+16.96%
2010	$56.63	$61.26	$50.26	$54.90	-2.95%
2009	$57.36	$64.76	$44.96	$56.57	-1.38%
2008	$46.84	$66.51	$39.16	$57.36	+21.89%
2007	$68.43	$76.95	$46.71	$47.06	-31.11%
2006from November	$75.09	$75.84	$67.88	$68.31	—

Month	Close	Change
September 2026	$421.51	-1.95%
August 2026	$429.88	+11.61%
July 2026	$385.16	+6.36%
June 2026	$362.12	+7.52%
May 2026	$336.79	-2.73%
April 2026	$346.25	-1.59%

Month	Close	Change
March 2026	$351.85	-9.35%
February 2026	$388.16	+13.54%
January 2026	$341.88	+4.45%
December 2025	$327.31	-5.25%
November 2025	$345.46	+15.76%
October 2025	$298.43	+9.32%

Amgen Inc.

Financials

Analyst & Risk

Recent rating changes

Financial documents

Amgen Inc. performance

Amgen Inc. all-time high and low

52-week range

Amgen Inc. risk metrics

Amgen Inc. drawdown from peak

Amgen Inc. seasonality

Amgen Inc. price history

Frequently asked questions about Amgen Inc.

What is the price of Amgen Inc. today?

What is the all-time high of Amgen Inc.?

How much has Amgen Inc. gained this year?

Recent news

Learn the terms

Live discussion

Amgen Inc. performance

Amgen Inc. all-time high and low

52-week range

Amgen Inc. risk metrics

Amgen Inc. drawdown from peak

Amgen Inc. seasonality

Amgen Inc. price history

Frequently asked questions about Amgen Inc.

What is the price of Amgen Inc. today?

What is the all-time high of Amgen Inc.?

How much has Amgen Inc. gained this year?

Amgen Inc. month-end closes

How volatile is Amgen Inc.?

What was the biggest price drop for Amgen Inc.?

Which month has historically been best for Amgen Inc.?